US Stock Market Move | Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA.US) surged nearly 13% in pre-market trading, with Q3 revenue and adjusted earnings per share both exceeding expectations.

On Wednesday, Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA.US) surged nearly 13% in pre-market trading, reaching $23.10. Teva Pharmaceutical Industries Limited Sponsored ADR reported Q3 revenue of $4.48 billion, exceeding market expectations of $4.34 billion; adjusted earnings per share were $0.78, higher than the market's expectation of $0.68. The company forecasts full-year revenue for the fiscal year 2025 to be in the range of $16.8 billion to $17 billion, while FactSet's estimate is $16.83 billion. The company has raised its adjusted earnings per share guidance for the fiscal year 2025 from $2.50-2.60 to $2.55-2.65, with analysts expecting $2.58.